[go: up one dir, main page]

BR0209325A - Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo - Google Patents

Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo

Info

Publication number
BR0209325A
BR0209325A BR0209325-1A BR0209325A BR0209325A BR 0209325 A BR0209325 A BR 0209325A BR 0209325 A BR0209325 A BR 0209325A BR 0209325 A BR0209325 A BR 0209325A
Authority
BR
Brazil
Prior art keywords
dosage form
amorphous
nelfinavir mesylate
pharmaceutical dosage
amorphous nelfinavir
Prior art date
Application number
BR0209325-1A
Other languages
English (en)
Inventor
Martin Howard Infeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0209325A publication Critical patent/BR0209325A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMA DE DOSAGEM FARMACêUTICA DE MESILATO DE NELFINAVIR AMORFO". A presente invenção se refere a uma forma de dosagem farmacêutica oral unitária sólida de mesilato de nelfinavir amorfo, compreendendo mesilato de nelfinavir amorfo e um copolímero em bloco sintético não-iónico, solúvel em água e farmaceuticamente aceitável de óxido de etileno e óxido de propileno, dito copolímero tendo um ponto de fusão de pelo menos 40<198>C. A invenção também proporciona um processo de granulação de material fundido para fabricação da forma de dosagem.
BR0209325-1A 2001-05-03 2002-04-29 Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo BR0209325A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number Publication Date
BR0209325A true BR0209325A (pt) 2004-07-20

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209325-1A BR0209325A (pt) 2001-05-03 2002-04-29 Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo

Country Status (36)

Country Link
US (1) US7014866B2 (pt)
EP (1) EP1390063B1 (pt)
JP (1) JP4101661B2 (pt)
KR (1) KR100554816B1 (pt)
CN (1) CN1255185C (pt)
AR (1) AR034320A1 (pt)
AT (1) ATE282428T1 (pt)
BG (1) BG108311A (pt)
BR (1) BR0209325A (pt)
CA (1) CA2444116C (pt)
CZ (1) CZ20033211A3 (pt)
DE (1) DE60201988T2 (pt)
EA (1) EA006627B1 (pt)
EC (1) ECSP034827A (pt)
ES (1) ES2231717T3 (pt)
GE (1) GEP20053466B (pt)
GT (1) GT200200079A (pt)
HR (1) HRP20030873B1 (pt)
HU (1) HU229938B1 (pt)
IL (2) IL158306A0 (pt)
IS (1) IS7010A (pt)
JO (1) JO2401B1 (pt)
MA (1) MA27018A1 (pt)
MX (1) MXPA03009971A (pt)
MY (1) MY128509A (pt)
NO (1) NO20034689D0 (pt)
NZ (1) NZ528689A (pt)
PA (1) PA8544501A1 (pt)
PE (1) PE20021159A1 (pt)
PL (1) PL366998A1 (pt)
PT (1) PT1390063E (pt)
RS (1) RS83503A (pt)
SK (1) SK14572003A3 (pt)
TW (1) TWI234461B (pt)
UA (1) UA76463C2 (pt)
WO (1) WO2002089835A2 (pt)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
US7495011B2 (en) 2003-07-15 2009-02-24 Arigen Pharmaceuticals, Inc. Anti-coronavirus drug
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8974823B2 (en) * 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
WO2006060711A2 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
DE602006011485D1 (de) * 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
DK1962808T3 (da) * 2005-12-14 2010-11-08 Hoffmann La Roche HCV prodrug-formulering
CA2660374A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
AU2007284615B2 (en) * 2006-08-16 2011-10-27 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008131259A1 (en) * 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2527336A1 (en) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterated analogues of cilostazol
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
EP2152709B1 (en) 2007-05-01 2012-02-22 Concert Pharmaceuticals Inc. Morphinan compounds
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
FI3825306T3 (fi) 2007-05-01 2023-08-23 Concert Pharmaceuticals Inc Morfinaaniyhdisteitä
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
AU2008267048C1 (en) 2007-06-12 2013-01-17 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CN101896161A (zh) * 2007-10-19 2010-11-24 普渡（大学）研究基金 结晶化合物的固体制剂
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
EA019088B1 (ru) 2008-02-29 2014-01-30 Консерт Фармасьютикалз, Инк. Замещенные производные дейтерированных ксантинов и их применение
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
US8710072B2 (en) 2008-09-19 2014-04-29 Concert Pharmaceuticals, Inc. Morphinan compounds
EP2397159A3 (en) 2008-10-30 2012-02-22 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
EP2397158B1 (en) 2008-10-30 2016-04-13 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
BRPI0921650A2 (pt) 2008-11-04 2019-07-30 Anchor Therapeutics Inc compostos receptores de cxcr4
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP2579858B1 (en) * 2010-06-14 2014-05-21 Ratiopharm GmbH Ivabradine-containing pharmaceutical composition
EP2616467A1 (en) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ES2758028T3 (es) 2011-05-18 2020-05-04 Vertex Pharmaceuticals Europe Ltd Derivados deuterados de ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
PL3882249T3 (pl) 2012-06-15 2025-09-08 Sun Pharmaceutical Industries, Inc. Pochodne deuterowane ruksolitynibu
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP3492472A1 (en) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
JP2016503798A (ja) 2012-12-20 2016-02-08 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ａｌｋ阻害剤
EP3470070B1 (en) 2012-12-21 2021-04-28 Mayo Foundation for Medical Education and Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014237569B2 (en) 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
EA032094B1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
US20160159861A1 (en) 2013-07-18 2016-06-09 Anchor Therapeutics, Inc. APJ Receptor Compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
CN106459004B (zh) 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
CA2994169A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
UA124619C2 (uk) 2015-09-21 2021-10-20 Вертекс Фармасьютікалз (Юроп) Лімітед Введення дейтерованих підсилювачів cftr
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
MX391898B (es) 2015-12-09 2025-03-21 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos.
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
SMT202400389T1 (it) 2016-05-04 2024-11-15 Sun Pharmaceutical Industries Inc Trattamento dei disturbi di perdita dei capelli con inibitori delle jak deuterati
PT3825307T (pt) 2016-07-04 2022-08-26 Avanir Pharmaceuticals Inc Métodos para a síntese de dextrometorfano deuterado
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
WO2018119076A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
BR112019024177A2 (pt) 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN114144229A (zh) 2019-04-10 2022-03-04 梅约医学教育与研究基金会 心血管功能障碍的性别依赖性治疗方法和材料
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
EP4236956A1 (en) 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US20240307401A1 (en) 2021-08-12 2024-09-19 Sun Pharmaceeutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
AU2023265574A1 (en) 2022-05-04 2024-12-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
ATE286721T1 (de) * 1997-09-19 2005-01-15 Shire Lab Inc Feste lösungskügelchen
EP1227797B1 (en) * 1999-11-12 2005-01-12 Abbott Laboratories Solid dispersion pharmaceutical formulations
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
DE60201988T2 (de) 2005-12-15
JP2004527569A (ja) 2004-09-09
PE20021159A1 (es) 2002-12-20
US20030021840A1 (en) 2003-01-30
PT1390063E (pt) 2005-03-31
HRP20030873A2 (en) 2005-08-31
GT200200079A (es) 2002-12-05
EP1390063B1 (en) 2004-11-17
ECSP034827A (es) 2003-12-24
JP4101661B2 (ja) 2008-06-18
MY128509A (en) 2007-02-28
GEP20053466B (en) 2005-02-25
ATE282428T1 (de) 2004-12-15
RS83503A (sr) 2006-10-27
BG108311A (bg) 2004-12-30
EA006627B1 (ru) 2006-02-24
NZ528689A (en) 2005-03-24
IL158306A (en) 2008-11-03
NO20034689L (no) 2003-10-20
HUP0401238A3 (en) 2012-09-28
CN1255185C (zh) 2006-05-10
HU229938B1 (en) 2015-01-28
PL366998A1 (en) 2005-02-07
AR034320A1 (es) 2004-02-18
PA8544501A1 (es) 2002-11-18
MA27018A1 (fr) 2004-12-20
JO2401B1 (en) 2007-06-17
CA2444116C (en) 2009-01-20
IS7010A (is) 2003-10-30
TWI234461B (en) 2005-06-21
NO20034689D0 (no) 2003-10-20
HK1070285A1 (en) 2005-06-17
EP1390063A2 (en) 2004-02-25
HRP20030873B1 (en) 2006-04-30
UA76463C2 (en) 2006-08-15
IL158306A0 (en) 2004-05-12
WO2002089835A2 (en) 2002-11-14
CZ20033211A3 (cs) 2004-09-15
KR100554816B1 (ko) 2006-02-22
SK14572003A3 (sk) 2004-12-01
EA200301166A1 (ru) 2004-04-29
MXPA03009971A (es) 2004-02-12
US7014866B2 (en) 2006-03-21
DE60201988D1 (de) 2004-12-23
HUP0401238A2 (hu) 2004-12-28
KR20040007523A (ko) 2004-01-24
WO2002089835A3 (en) 2003-05-01
CN1547484A (zh) 2004-11-17
ES2231717T3 (es) 2005-05-16
CA2444116A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
BR0209325A (pt) Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
MA25842A1 (fr) Monohydrate cristallin, procede pour sa fabrication et son utilisation pour la fabrication d&#39;un medicament.
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
UA85564C2 (ru) Твердая фармацевтическая форма ингибитора протеазы вич и способ ее получения
DK1083902T3 (da) Nye galeniske præparatformer af meloxicam til oral administrering
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
DK1230236T3 (da) Forbindelse med væksthormonfrigörende egenskaber
CO5280222A1 (es) Composicion farmaceutica que comprende pemetrexed
EP1489075A4 (en) PROCESS FOR PREPARING PROPYLENE OXIDE
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores
BR0211250A (pt) Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação
MA26823A1 (fr) Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes.
AR011730A1 (es) UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I&#39;e göre bileşiklerin kullanımı
HUP0402654A2 (hu) 2-[(2&#39;-Halogén-3&#39;,5&#39;-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AR020998A1 (es) Formulaciones de liberacion controlada de metamizol
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
FR2843301B1 (fr) Forme galenique pour la delivrance colique de principes actifs
UY27278A1 (es) Forma de dosificación farmacéutica del mesilato de nelfinavir amorfo
FR2843955B1 (fr) Procede de preparation de poudres d&#39;oxydes inorganiques, de composes cristallins et utilisation de ces composes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]